Single-Dose, Open Label Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and tolerability of single doses of
treprostinil palmitil inhalation powder (TPIP) in participants with pulmonary arterial
hypertension (PAH)